Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.52 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1880125 | 0.87 | GRIA1 (0.60) | GRIA1GRIA3PDE4DCYP2A6 | |
| SCHEMBL1889436 | 0.84 | GRIA1 (0.61) | GRIA1GRIA3PDE4DCYP2A6CYP19A1 | |
| SCHEMBL1884597 | 0.82 | GRIA1 (0.52) | GRIA1GRIA3PDE4DCYP2A6CYP19A1 | |
| SCHEMBL1881066 | 0.81 | GRIA1 (0.58) | GRIA1GRIA3PDE4DCYP2A6 | |
| SCHEMBL1888734 | 0.81 | GRIA1 (0.58) | GRIA1GRIA3PDE4DCYP2A6 | |
| SCHEMBL1880459 | 0.80 | GRIA1 (0.50) | GRIA1GRIA3PDE4DCYP2A6 | |
| SCHEMBL1888200 | 0.80 | GRIA1 (0.52) | GRIA1GRIA3PDE4DCYP2A6 | |
| SCHEMBL1889112 | 0.80 | GRIA1 (0.65) | GRIA1GRIA3PDE4DCYP2A6 | |
| SCHEMBL1882179 | 0.79 | GRIA1 (0.59) | GRIA1GRIA3PDE4DCYP2A6 | |
| SCHEMBL1880856 | 0.79 | GRIA1 (0.56) | GRIA1GRIA3PDE4DCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1300396-B1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | EISAI R&D MAN CO LTD (JP) | 2009-01-14 | — | — | EP | claimed |
| US-20050245581-A1 | 1, 2-Dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | claimed |
| US-6949571-B2 | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof | EISAI CO., LTD. (JP) | 2005-09-27 | — | — | US | claimed |
| US-20040023973-A1 | 1,2-Dihydropyridine compounds, process for preparation of the same and use thereof | CATALYST PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | claimed |
| EP-1300396-A1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | Eisai Co., Ltd. (JP) | 2003-04-09 | — | — | EP | claimed |
| US-7939549-B2 | 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-10 | — | — | US | disclosed |
| EP-2254577-A1 | AMPA RECEPTOR ANTAGONISTS FOR EPILEPSY, MENTAL DISORDERS OR DEFICITS IN SENSORY ORGAN | Eisai R&D Management Co., Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20100297181-A1 | AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20100256191-A1 | AMPA RECEPTOR ANTAGONISTS AND ZONISAMIDE FOR EPILEPSY | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100222354-A1 | AMPA Receptor Antagonists and Aldose Reductase Inhibitors for Neuropathic Pain | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | US | disclosed |
| EP-2222296-A2 | AMPA RECEPTOR ANTAGONISTS AND ZONISAMIDE FOR EPILEPSY | Eisai R&D Management Co., Ltd. (JP) | 2010-09-01 | — | — | EP | disclosed |
| US-7759367-B2 | 1,2-dihydropiridin-2-one compounds such as 3-(2-cyanophenyl)-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one, used as immunomodulators or antiinflammatory agents, and for the prevention or treatment of neurodegenerative diseases, such as demyelinating disorders | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| WO-2006107860-A2 | DIHYDROPYRIDINE COMPOUNDS AND COMPOSITIONS FOR HEADACHES | EISAI CO., LTD. (JP) | 2006-10-12 | — | — | WO | disclosed |
| US-20060100249-A1 | Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20050245581-A1 | 1, 2-Dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-6949571-B2 | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof | EISAI CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| EP-1465626-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIHYDROPYRIDINONE COMPOUNDS AND AN IMMUNOREGULATORY OR AN ANTIINFLAMMATORY AGENT AND THEIR USES | Eisai Co., Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
| US-20040023973-A1 | 1,2-Dihydropyridine compounds, process for preparation of the same and use thereof | CATALYST PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003047577-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIHYDROPYRIDINONE COMPOUNDS AND AN IMMUNOREGULATORY OR AN ANTIINFLAMMATORY AGENT AND THEIR USES | EISAI CO LTD (JP) | 2003-06-12 | — | — | WO | disclosed |
| EP-1300396-A1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | Eisai Co., Ltd. (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023973-A1 | 1,2-Dihydropyridine compounds, process for preparation of the same and use thereof | GRIK1, GRIK2, GRIK4 | GRIA1 14/4885GRIA3 58/4885PDE4D 2584/4885 |
| US-20050245581-A1 | 1, 2-Dihydropyridine compounds, manufacturing method thereof and use thereof | GRIK1, GRIK2, GRIK5 | GRIA1 24/4885GRIA3 46/4885PDE4D 1607/4885 |
| US-20100256191-A1 | AMPA RECEPTOR ANTAGONISTS AND ZONISAMIDE FOR EPILEPSY | GRIK5, GABRE, GABRA5 | GRIA1 47/4885GRIA3 34/4885PDE4D 1445/4885 |
| US-20060100249-A1 | Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses | QDPR, PMP22, MAG | GRIA1 449/4885GRIA3 663/4885PDE4D 679/4885 |
| US-20100222354-A1 | AMPA Receptor Antagonists and Aldose Reductase Inhibitors for Neuropathic Pain | AKR1B1, AKR1C1, AKR1C2 | GRIA1 24/4885GRIA3 56/4885PDE4D 2521/4885 |
| US-20100297181-A1 | AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ | GRIK5, GRIK4, GRIK1 | GRIA1 34/4885GRIA3 31/4885PDE4D 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.